Home

Post event on demand access to recorded presentations will be available to all attendees 5 working days from the end date of the event.

overview

For the latest COVID-19 Travel restrictions and recommendations please click here

SMi presents the Inaugural Transdermal and Microneedle Drug Delivery Conference
24th to 25th January, 2022 | Virtual Conference: Online Access Only
-------------------------------------------------------------------------

SMi is proud to present the Transdermal and Microneedle Drug Delivery Conference, taking place on the 24th to 25th January 2022.  Transdermal and Microneedle Drug Delivery Conference will explore real world applications of microneedles in drug delivery and strategies for device design while engaging in the latest innovations in device design and formulation with case studies from thought leaders.

The conference will consider key developments in the transdermal drug delivery field, including the innovations in microneedle technology for a COVID-19 vaccine and opportunities for development in cancer vaccine delivery, advances in microarray patches, and microneedle-based diagnostics. Key regulatory updates including guidance on classification of microneedle devices and considerations for ensuring quality will be presented by regulatory experts for a comprehensive outlook of this exciting and ever-growing field, and the importance of considering human factors in order to enhance the user experience will be presented by industry experts.

This two-day agenda offers you peer-to-peer networking with leaders in transdermal and microneedle delivery. We look forward to welcoming you to the conference in January.

  • Gain insight into developments in microneedles for drug delivery and diagnostics
  • Hear key regulatory updates from regulatory bodies including FDA and WHO on guidance for regulatory compliance
  • Explore new applications of microneedle technology in vaccinations
  • Discover advances in design and application of transdermal patches
  • Explore and benchmark against industry developments through case studies and real world examples in device development for microneedles
  • Drug-Delivery  Device Developers
  • Microneedle Device Developers
  • Transdermal Delivery  Developers
  • Microarray Patch Developers
  • Medical Device Engineers
  • Primary Packaging Material Designers
  • Secondary Packagers
  • Smart Device Developers
  • Training Device Developers
  • Device-Safety Solution Providers
  • Drug Developers
  • Transdermal Drug Product Developers


Previous attendees include:

AbbVie; Alnylam Pharmaceuticals; Amgen; Aptar Pharma; AstraZeneca; Bayer AG; BD Medical; Bd Medical-Pharmaceutical Systems; Becton dickinson; Becton Dickinson (BD); Bespak Europe Ltd; Boehringer Ingelheim; Boehringer Ingelheim GmbH; Boehringer Ingelheim Pharma GmbH & Co. KG; BSI; BSI Group; Cardiff University; CSL Behring AG; Eveon; F. Hoffman-La Roche Ltd.; F. Hoffmann-La Roche Ltd.; Ferring Pharmaceuiticals Pvt. Ltd.; FERRING PHARMACEUTICALS PVT LTD; Gerresheimer Buende GmbH; GlaxoSmithKline; GlaxoSmithKline (GSK); GSK; Haughton Design Ltd; Institute BCN Esthetics, S.L.; Ipsen; Ipsen Group; IPSEN Pharmsciences; Janssen; Janssen Pharmaceutica NV; Janssen Pharmaceutical Companies of Johnson and Johnson; Janssen Research and Development, LLC; Johnson & Johnson (Janssen Pharmaceutical); kaleo, Inc.; LEO Pharma A/S; Medicines & Healthcare Products Regulatory Agency (MHRA); MedinCell; Merck; MHRA; Minapharm Pharmaceuticals; Nemera; Nipro PharmaPackaging Germany; Novartis; Novartis – Global Drug Development; Novartis Pharma AG; Novartis Pharmaceuticals; Novo Nordisk; Novo Nordisk A/S; Novo Nordisk Pharma; Owen Mumford; PCI Pharma Services; Pfizer; Pfizer Inc.; Pfizer Ltd UK; Pfizer UK Limited; Pfizer, INC.; Regeneron Pharmaceuticals, Inc.; Rhein Minapharm; Roche; RSK-Solutions/ RSK Life Science Media; Sanofi; Sanofi SWI; TERUMO coeporation; Teva Ltd; Teva Pharmaceuticals; Teva UK; Teva, Combination Products; TUV SUD Japan Ltd.; UCB; UCB Pharma; W.L. Gore & Associates, Inc.; West Pharmaceutical Services; Zeon Corporation; Zeon Europe GmbH; Zeon Specialty Materials

Conference programme

8:00 Registration and Coffee

9:00 Chair's Opening Remarks

Sanjiv Sharma

Sanjiv Sharma, Senior Lecturer in Medical Engineering, Swansea University
View Bio

9:10 Development of Smart Vaccine Patch for COVID19 vaccination

Sanjiv Sharma

Sanjiv Sharma, Senior Lecturer in Medical Engineering, Swansea University
View Bio

  • Repurposing microneedle technology for a COVID vaccine
  • Monitoring biomarkers in the skin compartment to assess efficacy of the vaccination
  • Microneedle patches for diagnostics and drug delivery
  • Evaluating advantages of microneedle technology: allowing for lower doses of the vaccine which contributes to low-cost manufacturing
  • Beyond the pandemic: expanding research to other diseases
  • 9:50 The MAP Center of Excellence Regulatory Working Group: A collaborative approach to help define the regulatory pathway for MAPs

    Sion Coulman

    Sion Coulman, Senior Lecturer, Cardiff University
    View Bio

  • A background to the MAP Regulatory Working Group (RWG)
  • An update on the activities of the MAP RWG, to include:
  • - Laboratory Developments; Developing new standardised Test Methods for MAP critical quality attributes
  • - Guidance; Helping to define the regulatory pathway for MAP development
     
  • 10:30 Morning Coffee

    11:00 GMP production of vaccine microneedles for clinical trials

    Jung-Hwan Park

    Jung-Hwan Park, Chief Technical Officer, QuadMedicine, Inc.
    View Bio

  • Recent KFDA guidance on medical microneedle
  • Choosing the right vaccine for MAP technology; why is the birth dose of hepatitis B vaccine microneedle important?
  • Aseptic process development and quality control for hepatitis B vaccine microneedle
  • Analysing strategies for developing vaccine microneedle
  • 11:20 Transdermal Delivery Systems as Drug Device Combination Products - Considerations for the biocompatibility testing program

  • Insight into biocompatibility evaluations supporting regulatory submissions of DDCP
  • Evaluating biocompatibility of Transdermal Delivery Systems / Microneedling Devices 
  • How to comply with requirements on extractable and leachable testing
  • Toxicological Risk Assessment approaches for E&L
  • Clemens Gunther

    Clemens Gunther, Director, Senior Expert Nonclinical Safety, Bayer AG
    View Bio

    12:00 Networking Lunch

    13:00 Developing differentiated, transdermal forms of high-value drugs

    Jake Lombardo

    Jake Lombardo, Co-Founder & CEO, Anodyne Nanotech, Inc
    View Bio

  • How does the Hero Patch work? A technology overview
  • Current challenges in the sustained delivery of macromolecules
  • A new class of microneedle – the cutting edge technology behind improved drug loading
  • Pre-clinical data and future possibilities of the Hero Patch delivery platform
     
  • 13:20 Prioritisation of microarray patches (MAPs) for vaccine delivery in low and middle-income countries

  • Compelling attributes of MAPs for vaccine delivery, and potential public health impact
  • MAPs, priority #1 as part of the Alliance Vaccine Innovation Prioritisation Strategy – methodology and rationale
  • The Alliance 5-year strategy and action plan for MAPs
  • Prioritisation of antigens for MAPs’ use in low and middle-income countries
  • Birgitte Giersing

    Birgitte Giersing, Team Lead, Vaccine prioritization and platforms, World Health Organization
    View Bio

    Marion Menozzi-Arnaud

    Marion Menozzi-Arnaud, Senior Specialist, Gavi
    View Bio

    14:00 A review and discussion of the ‘Beyond the Needle’ programme

    Kerry DeMarco

    Kerry DeMarco, DRIVe Start Program Innovation & Alliance Lead, Biomedical Advanced Research & Development Authority (BARDA)
    View Bio

  • The vision and need for change
  • The challenges to overcome – talking logistics
  • 14:20 PATH Microarray Patch Center of Excellence

    Courtney Jarrahian

    Courtney Jarrahian, Program Advisor, PATH
    View Bio

  • Overview and update from PATH’s Microarray Patch (MAP) Center of Excellence, an initiative to mobilize efforts to accelerate the development of MAPs for critical vaccines and essential medicines.
  • How the MAP delivery technology platform can maximize its impact by meeting global public health priorities.
  • Evaluations of user needs, human factors, cost-effectiveness modeling, and manufacturing approaches.
  • 15:00 Afternoon Tea

    15:30 Considerations for Microneedle System Development: An FDA Assessor’s Perspective

    Caroline Strasinger

    Caroline Strasinger, Master Reviewer, FDA
    View Bio

  • An overview of FDA perspectives on combination products, specifically transdermal and microneedle systems
  • Considerations for the manufacturing process and ensuring product quality of microneedle systems
  • Enhancing communication to move microneedle technology to the commercial market
  • 16:10 Advances in Vaccine Adjuvants and RNA Vaccines

    Derek O Hagan

    Derek O Hagan, Senior Advisor Vaccines, GSK
    View Bio

  • Licensed vaccines with adjuvants
  • RNA vaccines
  • Delivery systems
  • Discovery of next generation adjuvants
  • 16:50 Chair's Closing Remarks and Close of Day One

    Sanjiv Sharma

    Sanjiv Sharma, Senior Lecturer in Medical Engineering, Swansea University
    View Bio

    8:30 Registration and Coffee

    9:00 Chair's Opening Remarks

    Sanjiv Sharma

    Sanjiv Sharma, Senior Lecturer in Medical Engineering, Swansea University
    View Bio

    9:10 Microneedles for oral delivery

    Ester Caffarel-Salvador

    Ester Caffarel-Salvador, Associate Director, Regenerative Medicine, LEO Pharma A/S
    View Bio

  • Challenges of delivering to the gastrointestinal tract
  • Key device features for successful oral delivery
  • The landscape for oral drug delivery and microneedles
  • Patient perceptions of microneedles in the oral mucosa
  • 9:50 Human centered design of microneedle products

    James  Birchall

    James Birchall, Professor of Pharmaceutical Sciences and Deputy Head of School, Cardiff University
    View Bio

  • User studies and human factors in microneedle product development 
  • Addressing challenges in contraception technologies in low and middle income countries
  • Evaluating the usability and acceptability of a microneedle-based contraceptive
  • 10:30 Morning Coffee

    11:00 Nanoengineered microneedle arrays and their applications

    Ryan Donnelly

    Ryan Donnelly, Chair in Pharmaceutical Technology, Queen's University Belfast
    View Bio

  • The enhanced delivery of long-acting HIV medicines
  • Plasmonic photothermal therapy of basal cell carcionomma
     
  • 11:40 Transdermal and Microneedle Drug Delivery – Regulatory requirements in the EU

    Janet Koenig

    Janet Koenig, German CHMP Alternate, Head of the Unit Anaesthesiology, Algesiology, Rheumatology, Pneumology, ENT, German Federal Institute for Drugs and Medical Devices (BfArM)
    View Bio

  • General requirements for topical products in the context of a regulatory submission
  • Aspects to consider with respect to applications with Microneedle technology
  • Transdermal and Microneedle Drug Delivery Systems in paediatrics
  • 12:20 Networking Lunch

    13:20 Enabling More Efficacious and Accessible Vaccines with the MIMIX Patch Platform

    Michael Schrader

    Michael Schrader, CEO, Vaxess Technologies
    View Bio

  • Introduction to the biology of sustained intradermal delivery
  • Introduction to the MIMIX sustained intradermal delivery platform
  • Pre-clinical data review
  • Manufacturing and clinical trial program status
  • 14:00 Tissue Role in MAP Insertion Dynamics

    Tycho Speaker

    Tycho Speaker, Director, Drug Delivery and Biomaterials, AbbVie Ltd
    View Bio

  • Discussion of complex physical phenomena influencing MAP insertion
  • Tissue-specific considerations in development of a delivery system
  • Path to clinical studies and model selection
  • 14:40 Advanced microneedle patches for drug delivery

    Mark R Prausnitz

    Mark R Prausnitz, Regents Professor, Georgia Institute of Technology
    View Bio

  • Perspective on microneedle field as a whole
  • Novel microneedle patch designs
  • Case study on microneedle patch for drug delivery
  • 15:20 Afternoon Tea

    15:50 Vaxxas HD-MAP Update

    Tom Lake

    Tom Lake, SVP, Strategic Alliances and Commercialization, Vaxxas
    View Bio

  • Pre-clinical and Clinical Studies
  • Insights into Vaxxas’ needle-free vaccination technology
  • Manufacturing of Vaxxas’ HD-MAP
  • 16:30 Panel Discussion: Future outlook of transdermal drug delivery systems

  • Recent advances of microneedles for biomedical applications
  • Commercial opportunities in developing transdermal delivery systems
  • Overcoming challenges in scale up of manufacturing
  • Future uses of microneedles in pandemics: what would it take to make the technology ready?
  • Is the market ready for microneedle patch technology? Weighing the benefits and costs of transdermal delivery
  • Sanjiv Sharma

    Sanjiv Sharma, Senior Lecturer in Medical Engineering, Swansea University
    View Bio

    Tycho Speaker

    Tycho Speaker, Director, Drug Delivery and Biomaterials, AbbVie Ltd
    View Bio

    Courtney Jarrahian

    Courtney Jarrahian, Program Advisor, PATH
    View Bio

    Ester Caffarel-Salvador

    Ester Caffarel-Salvador, Associate Director, Regenerative Medicine, LEO Pharma A/S
    View Bio

    Michael Schrader

    Michael Schrader, CEO, Vaxess Technologies
    View Bio

    17:10 Chair's Closing Remarks and Close of Day Two

    Sanjiv Sharma

    Sanjiv Sharma, Senior Lecturer in Medical Engineering, Swansea University
    View Bio

    +

    FEATURED SPEAKERS

    Birgitte Giersing

    Birgitte Giersing

    Team Lead, Vaccine prioritization and platforms, World Health Organization
    Caroline Strasinger

    Caroline Strasinger

    Master Reviewer, FDA
    Courtney Jarrahian

    Courtney Jarrahian

    Program Advisor, PATH
    Derek O Hagan

    Derek O Hagan

    Senior Advisor Vaccines, GSK
    Ester Caffarel-Salvador

    Ester Caffarel-Salvador

    Associate Director, Regenerative Medicine, LEO Pharma A/S
    James  Birchall

    James Birchall

    Professor of Pharmaceutical Sciences and Deputy Head of School, Cardiff University
    Janet Koenig

    Janet Koenig

    German CHMP Alternate, Head of the Unit Anaesthesiology, Algesiology, Rheumatology, Pneumology, ENT, German Federal Institute for Drugs and Medical Devices (BfArM)
    Jung-Hwan Park

    Jung-Hwan Park

    Chief Technical Officer, QuadMedicine, Inc.
    Mark R Prausnitz

    Mark R Prausnitz

    Regents Professor, Georgia Institute of Technology
    Sachin Dubey

    Sachin Dubey

    Head of Drug Product and Analytical Development, Ichnos Sciences, SA
    Sanjiv Sharma

    Sanjiv Sharma

    Senior Lecturer in Medical Engineering, Swansea University
    Sion Coulman

    Sion Coulman

    Senior Lecturer, Cardiff University
    Tom Lake

    Tom Lake

    SVP, Strategic Alliances and Commercialization, Vaxxas
    Tycho Speaker

    Tycho Speaker

    Director, Drug Delivery and Biomaterials, AbbVie Ltd

    Birgitte Giersing

    Team Lead, Vaccine prioritization and platforms, World Health Organization
    Birgitte Giersing

    Birgitte Giersing leads the Vaccine Prioritisation and Platform work within the Product and Delivery Research Unit, in WHO’s Immunization Department. She is the secretariat for the Product Development for Vaccines Advisory Committee (PDVAC), working across a number of pathogens areas and vaccine platforms, and is the WHO focal point for the Vaccine Innovation Prioritisation Strategy (VIPS). She has approximately 20 years of vaccine product development experience, having led vaccine development programmes in the private and non-profit sector before joining WHO 6 years ago. She trained as a biochemist and performed her post-doctoral studies at the National Institutes of Health, USA in malaria vaccine development.

    Caroline Strasinger

    Master Reviewer, FDA
    Caroline Strasinger

    Dr. Strasinger is a Master Reviewer in CDER’s Office of Pharmaceutical Quality and is Chair of the FDA’s Transdermal Drug Working Group (TDWG). As Chair she is responsible for assuring the TDWG fulfills their mission of continuously improving the scientific premises for regulating product quality as it relates to clinical performance and the public availability of transdermal drug products. She began her career at FDA in 2009 and holds a PhD in Pharmaceutics and a BS in Chemical Engineering from the University of Kentucky.

    Clemens Gunther

    Director, Senior Expert Nonclinical Safety, Bayer AG
    Clemens Gunther

    Dr. Clemens Günther received his diploma in biology and doctorate for natural sciences from the Free University, Berlin-Germany.
    He started his professional career in 1990 at Schering AG, Berlin-Germany.
    From 2007 to 2013, Dr. Clemens Günther was Director and Head of Global Preclinical Development at Intendis GmbH, branded later-on as Bayer Dermatology.
    After integration of Intendis into Bayer in 2013, he became Director Nonclinical Safety Consumer Care and later-on Senior Expert Nonclinical Safety within the Division of Bayer Pharmaceuticals.
    Meanwhile Dr. Clemens Günther has gained over 30 years experience in drug development. He has been involved in nonclinical development and regulatory toxicology of small molecules, biologics, medical devices and drug device combination products in various medical indications.
     

    Courtney Jarrahian

    Program Advisor, PATH
    Courtney Jarrahian

    Courtney Jarrahian oversees a portfolio of projects at PATH advancing vaccine and pharmaceutical packaging and delivery technologies and is co-leader of the Microarray Patch Center of Excellence. In collaboration with private- and public-sector partners, she implements projects to develop, assess, and introduce combination products and medical devices, with a focus on user-centered design, technical development, human factors evaluation, health economics, manufacturing, regulatory pathways, and commercialization. She also serves on the World Health Organization’s (WHO) Delivery Technologies Working Group and is a member of PATH’s Research Ethics Committee.

    Derek O Hagan

    Senior Advisor Vaccines, GSK
    Derek O Hagan

    Derek O’Hagan, BPharm, MRPharmS, PhD.

    I am a Senior Advisor in R&D in GSK Vaccines, since 2018, and a GSK Fellow, since 2019. Prior to this I was the Global Head of Discovery Support and New Technology in GSK Vaccines. Until 2015, I was the Global Head of Vaccine Chemistry and Formulation Research for Novartis Vaccines. I have extensive experience on Vaccine Adjuvants, including R&D of those included in licensed products. I was a key member of the Team that established the program on RNA vaccines in Novartis, Cambridge, in 2009. I served on the Board of Scientific Advisors for the Controlled Release Society and I am a Fellow of the American Association of Pharmaceutical Scientists. I was awarded the Conference Science medal of the Royal Pharmaceutical Society of Great Britain in 1997, and the Young Investigator Research Achievement Award of the Controlled Release Society in 1999. I was also named as the ‘most inventive scientist’ in Chiron in 2004.
     

    Ester Caffarel-Salvador

    Associate Director, Regenerative Medicine, LEO Pharma A/S
    Ester Caffarel-Salvador

    Dr. Ester Caffarel-Salvador is a multidisciplinary scientist with a background in biotechnology and biochemistry. She was recognized by the MIT technology review with the Innovators under 35 award in 2019 and the Nova Talent award in 2021. As a postdoc in Professor Robert Langer's laboratory at MIT, she developed a novel pill design to administer insulin and other macro-molecules via oral delivery in collaboration with Novo Nordisk.
    Dr. Caffarel-Salvador is now an Associate Director of Regenerative Medicine at LEO Pharma. She is passionate about advocating on career development for women in science and is an advisor and mentor at various academic and entrepreneurial programs, both locally and internationally.
     

    Jake Lombardo

    Co-Founder & CEO, Anodyne Nanotech, Inc
    Jake Lombardo

    Jake has a unique combination of biomedical engineering experience and entrepreneurial acumen. He holds a B.S. of Biomedical Engineering from Union College and an M.Sc. of Innovation and Management from Tufts University. He couples this with leadership qualities developed over a lifetime of team sports to help set the direction of Anodyne.

    James Birchall

    Professor of Pharmaceutical Sciences and Deputy Head of School, Cardiff University
    James  Birchall

    James Birchall is Professor of Pharmaceutical Sciences and Deputy Head of the School of Pharmacy and Pharmaceutical Sciences, Cardiff University. Professor Birchall graduated from Bath University in 1993 and completed his PhD researching drug and DNA delivery systems in 1998 (Cardiff University). Current research includes pulmonary drug delivery and microneedle delivery of molecules, macromolecules, vaccines, auto-antigens and cells into skin for therapeutic, immunisation or immunotherapy applications.

    Professor Birchall has acted as Associate Editor of Critical Reviews in Therapeutic Drug Carrier Systems, a member of the Editorial Board of Expert Review of Medical Devices, a temporary advisor to the WHO and an expert advisor to the British Pharmacopoeia and conducted research funded by the EU, DFID, Bill and Melinda Gates Foundation, NIH, Wellcome Trust, EPSRC, MRC, Welsh Government, Royal Society, Innovate UK and various charities and pharmaceutical companies.

    Janet Koenig

    German CHMP Alternate, Head of the Unit Anaesthesiology, Algesiology, Rheumatology, Pneumology, ENT, German Federal Institute for Drugs and Medical Devices (BfArM)
    Janet Koenig

    Janet Koenig is the Head of Unit Anaesthesiology, Algesiology, Rheumatology, Pulmonology, ENT in the Division Licensing at the German Federal Institute for Drugs and Medical Devices (BfArM). Mrs. Koenig is also the German alternate member of the Committee for Medicinal Products for Human Use (CHMP) She received her M.D. at University of Goettingen Germany (1998) and her Board Certificate in Surgery at University Hospital of Bonn, Germany.

    Jung-Hwan Park

    Chief Technical Officer, QuadMedicine, Inc.
    Jung-Hwan Park

    Dr. Jung-Hwan Park, the CTO of QuadMedicine, is one of the leaders in the field of microneedles and has focused on developing microneedle-based drug delivery systems for over 20 years. Dr. Jung-Hwan Park completed his Ph.D. from Georgia Institute of Technology in biomedical engineering. Dr. Park currently holds a position as professor of Bio-Nano Technology at the Gachon University. He has also served as a president of the Korea Microneedle Research Association since 2016 and has provided consultation on microneedle product development to companies in different sectors.

    Kerry DeMarco

    DRIVe Start Program Innovation & Alliance Lead, Biomedical Advanced Research & Development Authority (BARDA)
    Kerry DeMarco

    Kerry DeMarco has been with BARDA since 2019 and currently leads the BARDA DRIVe Program & Innovation activities and runs the Beyond the Needle program. Prior to her time at BARDA, Dr. DeMarco was the Program Manager for the jointly funded BARDA/State of Texas pandemic response facility, the Texas A&M Center for Innovation in Advanced Development and Manufacturing (CIADM). Dr. DeMarco also spent over fifteen years supporting the U.S. Department of Defense Science & Technology development activities. Dr. DeMarco earned her Ph.D. in Kinesiology/Psychophysiology from the University of Maryland.

    Marion Menozzi-Arnaud

    Senior Specialist, Gavi
    Marion Menozzi-Arnaud

    Within the Gavi Secretariat and Market Shaping team, Marion is leading strategic cross portfolio projects in support of defining and/or accomplishing Gavi market shaping objectives. Especially, Marion is responsible for vaccine product innovation within the Secretariat as part of the Gavi Innovation Strategy, including leading the Vaccine Innovation Prioritisation Strategy (VIPS) - a partnership between the Gavi Secretariat, WHO, UNICEF, BMGF and PATH to drive vaccine product innovation. Prior to that, Marion was the Head of Pricing and Market Access, Biosimilars at Merck, and before that she was Principal in a boutique management consulting companies specialised in the pharmaceutical industry.

    Mark R Prausnitz

    Regents Professor, Georgia Institute of Technology
    Mark R Prausnitz

    Mark Prausnitz is Regents’ Professor and J. Erskine Love, Jr. Chair of Chemical & Biomolecular Engineering at the Georgia Institute of Technology. He earned a BS degree from Stanford University and PhD degree from MIT, both in chemical engineering. Dr. Prausnitz and colleagues carry out research on drug delivery using microneedles, lasers, ionic liquids and other microdevices for transdermal, ocular and intracellular delivery of drugs and vaccines. Dr. Prausnitz teaches courses on engineering calculations and pharmaceuticals. He has published almost 300 journal articles and has co-founded five start-up companies including Micron Biomedical and Clearside Biomedical.

    Michael Schrader

    CEO, Vaxess Technologies
    Michael Schrader

    Michael Schrader is the CEO of Vaxess, an NIH and VC-backed company bringing vaccines out of the clinic and into patients’ lives with the MIMIX Smart Release platform. MIMIX combines ease of administration with efficacy enhancements enabled by the "mimicry" of natural infections. The company has a pipeline of vaccines under development, including a world-first COVID + Influenza vaccine. Prior to Vaxess, Michael spent time at Google and Honda where he helped bring a range of products to market and earned more than fifteen patents. Michael received his B.S. in Mechanical Engineering from Purdue University and his M.B.A. from Harvard.

    Ryan Donnelly

    Chair in Pharmaceutical Technology, Queen's University Belfast
    Ryan Donnelly

    Professor Ryan Donnelly holds the Chair in Pharmaceutical Technology at Queen’s University Belfast and is Director of QUB’s interdisciplinary research programme Materials & Advanced Technologies for Healthcare (MATCH). His personal research is centred on design and physicochemical characterisation of advanced polymeric drug delivery systems for transdermal and intradermal drug delivery, with a strong emphasis on improving patient outcomes. He is currently developing a range of novel microneedle technologies through independent research, but also in collaboration with several major pharma partners. He has obtained substantial UK Research Council, charity and industrial funding and authored over 300 peer-reviewed publications (H-index = 58), including 6 patent applications, 6 textbooks, 23 book chapters and approximately 250 full papers. He has been an invited speaker at numerous national and international conferences. Professor Donnelly is Europe/Africa Editor of Drug Delivery & Translational Research and the Controlled Release Society’s Communications Chair. He has won the Academy of Pharmaceutical Science’s Innovative Science Award (2020), Evonik’s Resomer Award (2018), the Controlled Release Society’s Young Investigator Award (2016), BBSRC Innovator of the Year and the American Association of Pharmaceutical Scientists Pharmaceutical Research Meritorious Manuscript Award (2013), the GSK Emerging Scientist Award (2012) and the Royal Pharmaceutical Society’s Science Award (2011).

    Sachin Dubey

    Head of Drug Product and Analytical Development, Ichnos Sciences, SA
    Sachin Dubey

    I am presently working with Ichnos Sciences, Switzerland (A part of Glenmark Pharmaceuticals SA, Switzerland) and heading three major functions for the company – formulation, analytical, and drug product development groups. I have more than 15 years of experience in this area with > 9 years in an industrial setting (with previous global experience with Novozymes A/S Denmark and Glenmark Pharmaceutical SA Switzerland). Twelve products developed by me and my team are currently in clinical trials. These products are in different markets including the USA, EU, and Asia – this gave us very rich hands-on experience. In addition, I have 18 PCT patents, 24 publications in high-impact journals like Trends in Biotechnology, Journal of Controlled Release, Molecular Pharmaceutics, etc., 7 book chapters, and have been invited speaker on the topic in several international conferences (> 50). Industry and academia have equally recognized my contribution with 20 research awards including prestigious industry awards from Glenmark (Best innovation team – won twice), Merck (Innovation cup), Novartis (International bio camp), and the Swiss Society of Pharmaceutical Sciences (Best publication).

    Sanjiv Sharma

    Senior Lecturer in Medical Engineering, Swansea University
    Sanjiv Sharma

    Dr Sanjiv Sharma received his PhD on the development of analytical methods for determination of certain pharmaceuticals and their metabolites using miniaturised separation system in 2001. On completion of his fellowship he joined the Institute of Biomedical Engineering, Imperial College London to work with Professor Tony Cass in the area of Bionanotechnology and Biosensors. Here he developed minimally invasive microneedles, from photolithographic fabrication to high throughput fabrication, taking these microneedles from the lab to the clinic . Sanjiv was involved in a NIHR (i4i) funded research project involving clinical studies in healthy volunteers and participants with T1D with renowned Endocrinologist Clinicians; Professor Desmond Johnston and Professor Nick Oliver. He has published over 50 research articles and has patents filed in Germany, UK and the United States.
    Sanjiv is currently a Senior Lecturer in Medical Engineering in the College of Engineering at Swansea University. At Swansea, he is working on therapeutic drug delivery and diagnostic (theranostic) applications of polymeric microneedles.

    Sebastian Braun

    Head of Formulation Development, Head of Manufacturing MAP, LTS Lohmann Therapie-Systeme AG
    Sebastian Braun

    Dr. Sebastian Braun worked in the field of transdermal and dermal drug delivery for 15 years at different companies. A molecular biologist by training with a PhD in analytical chemistry and molecular biology, he started his career at a transdermal drug delivery company with a fundamental understanding of the biological workings of the skin. Spending the last 15 years at different transdermal and dermal drug delivery companies in various positions including head of formulation development, head of manufacturing and head of science and technology, he is now focused on microneedle development and manufacturing.
     

    Sion Coulman

    Senior Lecturer, Cardiff University
    Sion Coulman

    Sion is based at Cardiff University and has worked on microneedle-based delivery systems since 2002. He has been involved in the development of microneedle-based systems for both novel and established therapeutic candidates and is particularly interested in translation of the technology from laboratory prototypes to clinically useful products. He is a highly collaborative researcher with expertise that bridges the engineering, pharmaceutical science and medical research disciplines, and enjoys working in international multi-disciplinary teams. He has technical experience in both laboratory and end-user research and has parallel research interests in 3D bio-printing and capsule-based dry powder inhalers (DPIs).

    Tom Lake

    SVP, Strategic Alliances and Commercialization, Vaxxas
    Tom Lake

    Tom Lake, Senior Vice President, Strategic Alliances & Commercialization, Vaxxas. Tom Lake supports new businesses that improve access to immunizations. He brings vaccine industry experience in Product Development, Manufacturing, and Commercialization.

    Tycho Speaker

    Director, Drug Delivery and Biomaterials, AbbVie Ltd
    Tycho Speaker

    Tycho Speaker is currently Director, Drug Delivery and Biomaterials at AbbVie. He holds a doctorate in physical chemistry, which is the basis for a career spanning a variety of manufacturing and formulation roles. Work toward treatment of a rare skin disorder (Pachyonychia Congenita) included the development of a novel dissolvable microneedle technology, among a range of other patents and innovations in various stages of commercialization.

    Sponsors

    Key Media Partners

    Workshops

    Microneedles - tiny objects that make a huge impact
    Workshop

    Microneedles - tiny objects that make a huge impact

    Online Virtual Event
    26th January 2022
    Online Virtual Event , United Kingdom

    VENUE

    Online Virtual Event

    Online Virtual Event , Online Virtual Event , United Kingdom

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Preliminary Attendees

    Download

    SPEAKER INTERVIEW - Dr. Sebastian Braun, LTS Lohmann TherapieSysteme AG

    Download

    SPEAKER INTERVIEW - Michael Schrader, Vaxess Technologies

    Download

    Speaker Interview with Kerry Demarco, Biomedical Advanced Research & Development Authority (BARDA)

    Download

    Speaker Interview - ESTER CAFFAREL-SALVADOR, LEO Pharma A/S

    Download

    Speaker Interview - Mark Prausnitz, Georgia Institute of Technology

    Download

    Conference Co-Chair Letter

    Download

    Workshop Agendas

    Download

    Chair & Speaker Biographies

    Download

    Transdermal and Microneedle Drug Delivery 2022 Brochure

    Download

    Sponsors


    LTS

    Sponsors
    http://ltslohmann.de/en/

    LTS Lohmann Therapie-Systeme AG is a leading technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) for the pharmaceutical industry. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array Patches (MAP) for the intradermal delivery of large molecule, biological actives and vaccines.

    Founded in 1984, LTS operates today from two sites in Andernach, Germany and West Caldwell, NJ, USA and a representative office in Shanghai, China.



    QuadMedicine

    Sponsors
    https://www.quadmedicine.com

    WE CREATE BETTER TREATMENT TECHNOLOGY TO MAKE OUR LIVES HEALTHIER AND EASIER.

    QuadMedicine is a CDMO company, presenting a medical microneedle platform upon request from pharmaceutical companies. We have built our own sophisticated microneedle production technology based on equipment and tool design capabilities. Also, QuadMedicine is specialized in formulation technology and drug coating technology with minimal drug loss. We can enhance drug stability and efficacy during manufacturing and storage. Above all, QuadMedicine is the first company in the world to establish a microneedle production facility that meets the requirements for vaccine manufacturing. In this facility, most vaccines and synthetic drugs can be handled.


    Media Partners


    Technology Networks

    Key Media Partners
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Pharmiweb

    Key Media Partners
    http://www.pharmiweb.com

    Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.


    pharmaphorum

    Key Media Partners
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    World Pharma Today

    Key Media Partners
    http://www.worldpharmatoday.com



    pharmanews hq

    Key Media Partners
    http://http://pharmanewshq.com

    MedChemNet provides a unique and unparalleled platform for the medicinal chemistry community to share insights, discuss the latest research, and help move the field forward. MedChemNet covers all aspects of the drug discovery pipeline, from target identification and validation, through computer aided drug design (CADD), synthesis, screening and other biophysical techniques, to development of novel lead compounds and pre-clinical in vivo proof of concept. We also cover the design of synthetic drug delivery carriers and ADME/toxicology studies, as well as intellectual property and economic related issues. Website: Welcome to Pharma News HQ, the journal dedicated to the pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry. Pharmanewshq.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production.


    Pharmaceutical Technology

    Key Media Partners
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    World Pharma News

    Key Media Partners
    http://www.worldpharmanews.com/



    evvnt Ltd

    Key Media Partners
    http://www.evvnt.com

    evvnt enables people all over the world to fill their events utilising the most effective event listing sites on the web. Every minute, with little more than a click, more events and conferences appear in listings, in search engines and on mobile - discoverable by both category and location. With next to no effort customers of evvnt get better attendance, while consumers find events they previously had no idea existed. To date customers in 70 countries worldwide have submitted over 500,000 thousand event listings, created over 300,000 live links, and generated 1 million clicks to ticketing and registration pages. Learn more at www.evvnt.com


    Pharmacircle

    Key Media Partners
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Online Virtual Event

    Online Virtual Event
    United Kingdom

    Online Virtual Event

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out